Introduction
Vitamin D is a fat-soluble vitamin and steroid pro-hormone that plays an essential role in bone health. 1 Its biologically active form 1,25-hydroxyvitamin D regulates multiple signaling pathways involved in cell proliferation, apoptosis, differentiation and inflammation, and is therefore believed to have an anti-carcinogenic property. prospective studies (Ncase=12,824) found a summary relative risk of 1.04 (95% CI: 1.02-1.06) per 10 ng/ml increment in circulating 25(OH)D concentration. 4 Inferring causality from such studies is challenging because it is difficult to exclude reverse causality, confounding or measurement error.
Although the effect of circulating 25(OH)D on cancer risk can be demonstrated by traditional randomized controlled trials (RCT), large-scale RCTs are not currently widely available due to high cost and long duration. In the Women's Health Initiative trial, 36,282 postmenopausal women were randomized to 400 IU vitamin D or placebo, and a hazard ratio of 0.96 (95%CI: 0.85-1.09, P=0.55) for breast cancer was observed after 7 years' follow up. 5 For prostate cancer, only two comprehensive ongoing trials involving both men and women, the "VITAL" launched in 2010
(N=25,871) 6 and the "D-Health" launched in 2014 (N=21,315), 7 will provide an opportunity to clarify the role of vitamin D on male health outcomes upon completion. Yet, both RCTs are likely to be underpowered given the relatively low prostate cancer incidence.
Mendelian randomization (MR) analysis overcomes the limitations of conventional approaches by using genetic variants (single nucleotide polymorphisms, SNPs) as instrumental variables (IVs) for assessing the causal effect of a risk factor (exposure) on an outcome from observational data. 8 A two-sample MR obtain IV-exposure and IV-outcome associations from two different sets of identified from an earlier SUNLIGHT consortium genome-wide association study (GWAS).
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With the rapid expansion in sample sizes of GWAS, two additional vitamin D associated loci have been recently identified. 11 Incorporating these loci could improve the strength of genetic instrument and both the accuracy and precision of MR estimates. The statistical power can be further improved by using summary genetic data for breast and prostate cancer from recent larger GWASs.
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Therefore, we conducted an updated two-sample MR analysis to examine the effect of 25 
Methods

Data for IV-exposure
We retrieved summary data for the association between six SNPs and circulating 25(OH)D concentration from the SUNLIGHT meta-GWAS involving 79,366 discovery samples and 42,757
replication samples of European ancestry. Genome-wide analyses were performed within each cohort according to a uniform analysis plan. Specifically, additive genetic models using linear regression on natural-log transformed 25(OH)D were fitted, and a fixed-effects inverse variance weighted meta-analysis across the contributing cohorts was performed, with control for population structure within each cohort and quality control thresholds of minor allele frequency (MAF)>0.05, imputation info score>0.8, Hardy-Weinberg equilibrium (HWE)>1×10 -6 , and a minimum of 10,000 individuals contributing to each reported SNP-phenotype association. Information regarding the quality control and statistical analyses has been reported previously.
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Among the six SNPs, four were previously identified as being robustly associated with vitamin D (rs3755967 at GC, rs12785878 at NADSYN1/DHCR7, rs10741657 at CYP2R1, rs17216707 at CYP24A1). The other two were newly identified by the discovery sample (rs10745742 at AMDHD1, rs8018720 at SEC23A) and validated in the replication sample.
Data for IV-outcome
We retrieved summary data for associations of the six vitamin D proxy SNPs with breast and prostate cancer from the currently largest meta-GWAS of these outcomes conducted by the antigen values > 100 ng/ml). Our current sample size was 4.6-folds higher than that in Dimitrakopoulou et al. 9 .
Statistical analysis
MR uses SNPs as proxies for risk factors, assuming that SNPs are randomly allocated at conception, mirroring a randomization process; and that SNPs always precede disease onset thus eliminating reverse causality. Three important assumptions need to be met to ensure a valid IV. 16 The first is the relevance assumption, that the IVs should be associated with the exposure; the second assumption requires no association between IVs and confounders of the exposure-outcome relationship; and the third is the exclusion restriction assumption, indicating that genetic variants should affect the outcome only through the exposure. If all MR assumptions are satisfied, then a causal estimation can be made based on the observed IV-exposure and IV-outcome association.
We conducted a two-sample MR to test for a potential causal relationship between circulating 25(OH)D and risk of breast and prostate cancer. We also investigated cancer subtypes including ER+ and ER− breast cancer and advanced prostate cancer. We applied a number of MR methods including an inverse variance weighted average approach (IVW), 17 a maximum likelihood method, 18 MR-Egger regression, 19 and a weighted median approach. When there is considerable imprecision in the estimates, causal effect estimates from the IVW are over-precise, whereas the likelihood method gives appropriately-sized confidence intervals.
In addition, we performed MR-Egger regression to test for bias due to directional pleiotropy, where the average of the direct effects of the tested genetic variants on outcome is non-zero (i.e. a violation of exclusion restriction assumption). Under the INstrument Strength Independent of Direct Effect (InSIDE) assumption, the intercept of a weighted regression of ̂ on ̂ will be different than zero in the presence of directional pleiotropy, and the slope of that regression will be a consistent estimate of the causal effect of X on Y. 21 Complementary to MR-Egger, we also employed a weighted median method to derive causal effect estimates. This method provides consistent estimates even when up to 50% of the analyzed genetic variants are invalid IVs. We also employed a multivariable MR approach 22 to adjust for potential horizontal pleiotropy acting in particular through BMI, because rs10741657 has been associated with BMI (P=0.01), and BMI has been associated with 25(OH)D concentrations 23 and breast cancer risk 24 . Publicly available genetic data for BMI were retrieved from the GIANT consortium for 339,000 individuals (95% were of European descent). 25 Further, we performed a sensitivity analysis where we excluded one SNP at-a-time, and performed IVW on the rest five SNPs to identify the potential influence of outlying variants on the estimates.
Finally, we estimated the power of our study according to a method suggested by Brion et al.
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The six 25(OH)D associated SNPs collectively explained 2.84% of the variance of circulating vitamin D concentration. We fixed the type-I error rate at 0.05. Similar results were observed in the leave-one-out analysis where we iteratively removed one SNP each time and performed IVW using the remaining five SNPs (Table 4) .
Results
Discussion
In this study, we used an updated and stronger instrumental variable constructed from six SNPs overall SNP-heritability calculated using the linkage disequilibrium score regression analysis.
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Although improvement in the proportion of variability explained by IVs was minimal, our overall statistical power was considerably raised, using data from substantially augmented GWASs of breast and prostate cancer. We had 80% power at an alpha level of 0.05 to identify a 7% relative decreased breast cancer risk (i.e. an OR of 0.93) and an 8% relative decreased prostate cancer risk (i.e. an OR of 0.92) per 25nmol/L increase in circulating 25(OH)D. These effect sizes are comparable to the effects observed in meta-analyses of prospective studies for both cancers.
However, it is likely that the true causal effect of 25(OH)D is even weaker -if the true causal effect was less than 3%, a magnitude that is probably of limited clinical relevance -we only had a power of 23% for breast cancer, and 15% for prostate cancer, with our current sample size.
MR provides the opportunity to make causal inference between an exposure and an outcome using observational data. The validity of causal estimates requires several assumptions to be satisfied.
We selected the most significant independent SNPs identified by the largest 25(OH)D GWAS, so all were robustly associated with the exposure of interest. The six variants combined constitute a strong instrument, with an F statistic of 387. This would minimize any bias due to using a weak instrument in the analysis. Secondly, none of the six instrumental variables (or the proxy SNPs in high linkage disequilibrium with the six IVs at r 2 ≥0.8) used in our analysis were cited by the NHGRI-EBI Catalog of published GWAS as associated with known confounders of cancer risk, such as BMI, smoking, alcohol consumption, mammographic density or inflammation at α=10 -5 level. However, due to the lack of individual data, we were not able to test the association of 
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